Ask AI

Tardive Dyskinesia: Using Pharmacologic Principles to Create an Individualized Treatment Plan

Tardive dyskinesia (TD) presents important challenges in psychopharmacologic management, particularly for patients requiring long-term antipsychotic treatment. These downloadable slides from Psychopharmacology Update 2026 review TD risk factors, screening and assessment strategies, and evidence-based treatment approaches. Explore the pharmacology of VMAT2 inhibitors with practical considerations for dosing, drug interactions, and individualized treatment selection.

Psychopharmacology in TD

Activity Information

Released: November 18, 2026